An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease-Reference-Cited by-同舟云学术

An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease

Published:2023-07 Issue: Volume:232 Page:109525
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

Liu Xin,Lai Ling-yun,Chen Jiang-xia,Li Xiang,Wang Nan,Zhou Li-jun,Jiang Xiao-wen,Hu Xiao-long,Liu Wen-wu,Jiao Xin-ming,Qi Zhen-tong,Liu Wen-jie,Wu Li-meng,Huang Yao-guang,Xu Zi-hua,Zhao Qing-chun^ORCID

Funder

National Major Science and Technology Projects of China

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference36 articles.

1. DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications;Abbassi;Pharmacol. Ther.,2015

2. From combinations to multitarget-directed ligands: a continuum in Alzheimer's disease polypharmacology;Albertini;Med. Res. Rev.,2021

3. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau 231;Bayoumy;Alzheimer's Res. Ther.,2021

4. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases;Beurel;Pharmacol. Ther.,2015

5. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418;Bhat;J. Biol. Chem.,2003

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease;Journal of Medicinal Chemistry;2024-07-23

2. Research progress of PROTACs for neurodegenerative diseases therapy;Bioorganic Chemistry;2024-06

3. Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine;Pharmacological Reports;2024-05-17

4. Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment;Medicinal Research Reviews;2024-04-28

5. Discovery of novel harmine derivatives as GSK‐3β/DYRK1A dual inhibitors for Alzheimer's disease treatment;Archiv der Pharmazie;2023-11-27